174 related articles for article (PubMed ID: 38390201)
21. Trends in the Degree of Control and Treatment of Cardiovascular Risk Factors in People With Type 2 Diabetes in a Primary Care Setting in Catalonia During 2007-2018.
Mata-Cases M; Vlacho B; Real J; Puig-Treserra R; Bundó M; Franch-Nadal J; Mauricio D
Front Endocrinol (Lausanne); 2021; 12():810757. PubMed ID: 35082758
[TBL] [Abstract][Full Text] [Related]
22. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA
Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300
[TBL] [Abstract][Full Text] [Related]
23. Use of electronic health records for the management of diabetes and its risk factors in the Principality of Asturias from 2014 to 2018.
García-Villarino M; Lambert C; De la Hera JM; Torre ELM; Rodríguez-Lacín JMF; Delgado-Álvarez E
Endocrinol Diabetes Nutr (Engl Ed); 2024 May; 71(5):208-215. PubMed ID: 38897704
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of Low-density Lipoprotein Cholesterol Level-Guided Statin Treatment in Patients With Borderline Cardiovascular Risk.
Kohli-Lynch CN; Bellows BK; Thanassoulis G; Zhang Y; Pletcher MJ; Vittinghoff E; Pencina MJ; Kazi D; Sniderman AD; Moran AE
JAMA Cardiol; 2019 Oct; 4(10):969-977. PubMed ID: 31461121
[TBL] [Abstract][Full Text] [Related]
25. Women with type 2 diabetes have LDL cholesterol levels higher than those of men, regardless of their treatment and their cardiovascular risk level.
Paquet S; Sassenou J; Ringa V; Czernichow S; Zins M; Ozguler A; Rigal L
Nutr Metab Cardiovasc Dis; 2023 Jun; 33(6):1254-1262. PubMed ID: 37088650
[TBL] [Abstract][Full Text] [Related]
26. Long-Term Association of Low-Density Lipoprotein Cholesterol With Cardiovascular Mortality in Individuals at Low 10-Year Risk of Atherosclerotic Cardiovascular Disease.
Abdullah SM; Defina LF; Leonard D; Barlow CE; Radford NB; Willis BL; Rohatgi A; McGuire DK; de Lemos JA; Grundy SM; Berry JD; Khera A
Circulation; 2018 Nov; 138(21):2315-2325. PubMed ID: 30571575
[TBL] [Abstract][Full Text] [Related]
27. 10-Year Cardiovascular Risk in Patients With Newly Diagnosed Type 2 Diabetes Mellitus.
Gyldenkerne C; Mortensen MB; Kahlert J; Thrane PG; Warnakula Olesen KK; Sørensen HT; Thomsen RW; Maeng M
J Am Coll Cardiol; 2023 Oct; 82(16):1583-1594. PubMed ID: 37821168
[TBL] [Abstract][Full Text] [Related]
28. LDL-cholesterol target levels achievement in high-risk patients: An (un)expected gender bias.
Berteotti M; Profili F; Nreu B; Casolo G; Zuppiroli A; Mannucci E; Marcucci R; Francesconi P
Nutr Metab Cardiovasc Dis; 2024 Jan; 34(1):145-152. PubMed ID: 37996368
[TBL] [Abstract][Full Text] [Related]
29. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.
Vallejo-Vaz AJ; Robertson M; Catapano AL; Watts GF; Kastelein JJ; Packard CJ; Ford I; Ray KK
Circulation; 2017 Nov; 136(20):1878-1891. PubMed ID: 28877913
[TBL] [Abstract][Full Text] [Related]
30. Remnant Cholesterol and Cardiovascular Mortality in Patients With Type 2 Diabetes and Incident Diabetic Nephropathy.
Yu D; Wang Z; Zhang X; Qu B; Cai Y; Ma S; Zhao Z; Simmons D
J Clin Endocrinol Metab; 2021 Nov; 106(12):3546-3554. PubMed ID: 34291804
[TBL] [Abstract][Full Text] [Related]
31. Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics.
Morieri ML; Avogaro A; Fadini GP;
Cardiovasc Diabetol; 2020 Nov; 19(1):190. PubMed ID: 33172454
[TBL] [Abstract][Full Text] [Related]
32. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Jellinger PS; Handelsman Y; Rosenblit PD; Bloomgarden ZT; Fonseca VA; Garber AJ; Grunberger G; Guerin CK; Bell DSH; Mechanick JI; Pessah-Pollack R; Wyne K; Smith D; Brinton EA; Fazio S; Davidson M
Endocr Pract; 2017 Apr; 23(Suppl 2):1-87. PubMed ID: 28437620
[TBL] [Abstract][Full Text] [Related]
33. Suboptimal control of lipid levels: results from the non-interventional Centralized Pan-Russian Survey of the Undertreatment of Hypercholesterolemia II (CEPHEUS II).
Boytsov S; Logunova N; Khomitskaya Y;
Cardiovasc Diabetol; 2017 Dec; 16(1):158. PubMed ID: 29246151
[TBL] [Abstract][Full Text] [Related]
34. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.
Downs JR; Clearfield M; Weis S; Whitney E; Shapiro DR; Beere PA; Langendorfer A; Stein EA; Kruyer W; Gotto AM
JAMA; 1998 May; 279(20):1615-22. PubMed ID: 9613910
[TBL] [Abstract][Full Text] [Related]
35. Prescription of lipid-lowering medications for patients with type 2 diabetes mellitus and risk-associated LDL cholesterol: a nationwide study of guideline adherence from the Swedish National Diabetes Register.
Karlsson SA; Franzén S; Svensson AM; Miftaraj M; Eliasson B; Andersson Sundell K
BMC Health Serv Res; 2018 Nov; 18(1):900. PubMed ID: 30486824
[TBL] [Abstract][Full Text] [Related]
36. Sex differences in cardiovascular risk, lifestyle, and psychological factors in patients with type 2 diabetes: the Fukuoka Diabetes Registry.
Ohkuma T; Iwase M; Fujii H; Kitazono T
Biol Sex Differ; 2023 May; 14(1):32. PubMed ID: 37211595
[TBL] [Abstract][Full Text] [Related]
37. [Blood glucose control and cardiovascular risk factors in type 2 diabetic patients with cardiovascular disease in Spain, and its treatment pattern, according to gender: CODICE study].
Gómez García MC; Franch-Nadal J; Millaruelo Trillo JM; Cos-Claramunt FX; Avila Lachica L; Buil Cosiales P
Semergen; 2020 Mar; 46(2):125-135. PubMed ID: 31399388
[TBL] [Abstract][Full Text] [Related]
38. Sex differences in cardiometabolic risk factors, pharmacological treatment and risk factor control in type 2 diabetes: findings from the Dutch Diabetes Pearl cohort.
de Jong M; Oskam MJ; Sep SJS; Ozcan B; Rutters F; Sijbrands EJG; Elders PJM; Siegelaar SE; DeVries JH; Tack CJ; Schroijen M; de Valk HW; Abbink EJ; Stehouwer CDA; Jazet I; Wolffenbuttel BHR; Peters SAE; Schram MT;
BMJ Open Diabetes Res Care; 2020 Oct; 8(1):. PubMed ID: 33023896
[TBL] [Abstract][Full Text] [Related]
39. Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol.
Colhoun HM; Leiter LA; Müller-Wieland D; Cariou B; Ray KK; Tinahones FJ; Domenger C; Letierce A; Israel M; Samuel R; Del Prato S
Cardiovasc Diabetol; 2020 Feb; 19(1):14. PubMed ID: 32035487
[TBL] [Abstract][Full Text] [Related]
40. Small Dense Low-Density Lipoprotein Level in Newly Diagnosed Type 2 Diabetes Mellitus Patients With Normal Low-Density Lipoprotein.
Juhi A; Jha K; Mondal H
Cureus; 2023 Jan; 15(1):e33924. PubMed ID: 36819362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
